No abstract

Purpose of Review The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination. Recent Findings Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1–20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination. Summary Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.

reticular and arcuate patterns are only seen in photoexposed areas. Diffuse isolated pattern is the only arrangement seen in LPPI, unlike LPP, in photoexposed areas where the presence of multiple patterns is the predominant characteristic. Erythema and telangiectasia are more significant in LPP of photoexposed areas. We believe that LPP is an underreported skin disorder.We showed that it is not so rare in the Caucasian population and that it may have a late onset. It has a chronic course and a severe social impact due to aesthetic disfigurement. Therapeutic management of LPP is often challenging. Treatment can lead to stabilization of the disease, but the pigmentation is often resistant. It is important to avoid trigger factors. It is important to identify associated comorbidities.

No abstract